Yuesai Biotechnology has completed nearly 100 million yuan in Series A+ financing.

Recently, cell therapy company Leap Biosciences completed nearly 100 million yuan in Series A+ funding, led by Shanghai Guotou Xianhao and Pudong Venture Group. Leap Biosciences was founded in 2021, focusing on the development of cell therapy drugs based on human pluripotent stem cell technology, covering neurodegenerative diseases, rare diseases, and tumors. The company has previously received support from well-known institutions such as Hillhouse Capital and Tencent Investments.